Find out what Breast Cancer Care is saying about the latest drug treatments, research papers and health policy issues.

If you’re a journalist working on a story and need an expert quote, call us on 0345 092 0807 (out of hours 07702 901 334).

Responding to the decision by NICE today (Wednesday 31 January) to not recommend fulvestrant (Faslodex) for use by the NHS in England*, Samia al...

31 January 2018

Discussing NICE’s draft updated guideline on early and locally advanced breast cancer, Samia al Qadhi, Chief Executive of Breast Cancer Care,...

24 January 2018

Responding to a study that has found no association between night-time light levels and breast cancer risk, Rachel Rawson, Senior Clinical Nurse...

24 January 2018

Responding to the findings (published in the Journal of the National Cancer Institute) that screening the entire population for breast and ovarian...

18 January 2018

Responding to updated NICE draft guidance on breast cancer profiling tests Dr Emma Pennery, Clinical Director of Breast Cancer Care, says: “...

11 January 2018

Responding to the decision by NICE (on Thursday 14 December 2017) to not recommend fulvestrant (Faslodex) for use by the NHS in England*, Samia al...

19 December 2017

Responding to findings presented at the 2017 San Antonio Breast Cancer Symposium on weight loss and breast cancer risk, Addie Mitchell, Clinical...

12 December 2017

Responding to the news that the Scottish Medicines Consortium (SMC) has approved palbociclib (Ibrance)1 for use by NHS Scotland, Angela Harris, Head...

11 December 2017

Responding to new ONS figures showing that one year survival rates for breast cancer in England have reached 96.7%, Dr Emma Pennery, Clinical...

30 November 2017